Lipid nanoparticles (LNPs) are currently the most clinically advanced nonviral carriers for the delivery of small interfering RNA (siRNA). Free siRNA molecules suffer from unfavorable physicochemical characteristics and rapid clearance mechanisms, ...

Macrophage hyperfunction or dysfunction is tightly associated with various diseases, such as osteoporosis, inflammatory disorder, and cancers. However, nearly all conventional drug delivery system (DDS) nanocarriers utilize endocytosis for ent...

Nanopharmaceuticals aim at translating the unique features of nano-scale materials into therapeutic products and consequently their development relies critically on the progression in manufacturing technology to allow scalable processes complying w...

Lipid-based nanobiomaterials as liposomes and lipid nanoparticles (LNPs) are the most widely used nanocarriers for drug delivery systems (DDSs). Extracellular vesicles (EVs) and exosomes are also expected to be applied as DDS nanocarriers. The perf...

The advancement of nanotechnology toward more sophisticated bioinspired approaches has highlighted the gap between the advantages of biomimetic and biohybrid platforms and the availability of manufacturing processes to scale up their production. Th...

The process of optimization and fabrication of nanoparticle synthesis for preclinical studies can be challenging and time consuming. Traditional small scale laboratory synthesis techniques suffer from batch to batch variability. Additionally, the p...

Vesicle formation by a staggered herringbone microfluidic mixer was investigated in comparison to a sonication-extrusion method. Experiments focused on the incorporation efficiency of lipid components, on dye entrapment efficiency, and on the barri...

Currently, clinically approved medicines with liposomal formulations have a combined annual revenue of approximately $100 million USD, but their difficult and expensive production methods make more widespread use prohibitive. Microfluidic devi...

Understanding the effect of liposome size on tendency for accumulation in tumor tissue requires preparation of defined populations of different sized particles. However, controlling the size distributions without changing the lipid composition is d...

Liposomes are lipid-based supramolecular assemblies that can be engineered into efficacious drug carriers. Typically described as bilayer systems with an aqueous core, liposomes can increase the therapeutic index of a given drug molecule by decreas...

Liposomes have been the centre of attention in research due to their potential to act as drug delivery systems. Although its versatility and manufacturing processes are still not scalable and reproducible.

A wide range of studies have shown that liposomes can act as suitable adjuvants for a range of vaccine antigens. Properties such as their amphiphilic character and biphasic nature allow them to incorporate antigens within the lipid bilayer, on the ...

Quantification of the lipid content in liposomal adjuvants for subunit vaccine formulation is of extreme importance, since this concentration impacts both efficacy and stability. In this paper, we outline a high performance liquid chromatography-ev...

Molecular self-assembly has enabled the fabrication of biologically inspired, advanced nanostructures as lipid-based nanovesicles (L-NVs). The oldest L-NVs, liposomes, have been widely proposed as potential candidates for drug delivery, diagnostic ...

Microfluidic devices are mircoscale fluidic circuits used to manipulate liquids at the nanoliter scale. The ability to control the mixing of fluids and the continuous nature of the process make it apt for solvent/antisolvent precipitation of drug-d...

Small interfering RNAs (siRNAs) therapeutics has advanced into clinical trials for liver diseases and solid tumors, but remain a challenge for manipulating leukocytes fate due to lack of specificity and safety issues. Leukocytes ingest pathogens an...

Liposomes not only offer the ability to enhance drug delivery, but can effectively act as vaccine delivery systems and adjuvants. Their flexibility in size, charge, bilayer rigidity and composition allow for targeted antigen delivery via ...

Described first in the 1960s by Bangham1 and understood as a potential drug delivery system in the early 1970s,2−4 the liposome has since become integral to research and clinical applications in the field of nanomedicine.

Besides their well-described use as delivery systems for water-soluble drugs, liposomes have the ability to act as a solubilizing agent for drugs with low aqueous solubility. However, a key limitation in exploiting liposome technology is ...

Previous studies from this group have shown that limit size lipid-based systems—defined as the smallest achievable aggregates compatible with the packing properties of their molecular constituents—can be efficiently produced using a&nbs...

Liposomes are an established delivery system for therapeutics, but liposome production methods have suffered from issues relating to quality and scalability that must be overcome before liposomes can be widely employed in clinical applications.

The discovery of RNA interference (RNAi) in mammalian cells has created a new class of therapeutics based on the reversible silencing of specific disease-causing genes.

The potency of drug delivery systems can heavily rely on their ability to penetrate poorly vascularized tissues such as tumors, following intravenous administration. The drug delivery vehicle’s size greatly impacts this phenomenon.